New Data Shows STELARA® (Ustekinumab) Maintained Clinical Response And Remission After Two Years Of Treatment In Patients With Moderate To Severe Crohn’s Disease
- EMEA Innovative Medicine
- New Data Shows STELARA® (Ustekinumab) Maintained Clinical Response And Remission After Two Years Of Treatment In Patients With Moderate To Severe Crohn’s Disease
New Data Shows STELARA® (Ustekinumab) Maintained Clinical Response And Remission After Two Years Of Treatment In Patients With Moderate To Severe Crohn’s Disease
- X (Twitter)
Copy link